Vascular events may predict the prognosis of patients with chronic myeloid leukemia

To the Editor

Mori et al. reported the pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia (CML), and we read with great interest the paper [1]. The patient developed severe vascular toxicities due to second generation tyrosine kinase inhibitors (TKIs) (hypertensive nephrosclerosis due to nilotinib, and heart failure due to dasatinib), but achieved a favorable treatment response with MR4.5 and maintained treatment-free remission (TFR). The phosphoproteomic signature in endothelial cells, which can regulate leukemic stem cells in CML [2], reflects the vascular toxicities of TKIs [3]. Considering the treatment response and vascular toxicity in the patient, the impairment of CML leukemic stem cell harboring from endothelial cells by TKIs may be involved in the treatment response or maintenance of TFR via endothelial dysfunction by TKIs. Although patients with severe renal insufficiency like the present patient are generally excluded from clinical trial settings, real world cohort data to investigate treatment responses or TFRs are necessary to clarify the association between vascular adverse events and treatment response or achievement of TFR in patients with CML.

References

  1. 1.

    Mori J, Oshima K, Tanimoto T, Ishizuka H, Kimura S, Miura M. Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease. Int J Hematol. 2020. https://doi.org/10.1007/s12185-020-02846-5.

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Zhang B, Nguyen LXT, Li L, Zhao D, Kumar B, Wu H, et al. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med. 2018;24:450–62.

    CAS  Article  Google Scholar 

  3. 3.

    Gopal S, Lu Q, Man JJ, Baur W, Rao SP, Litichevskiy L, et al. A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML. Blood Adv. 2018;2:1680–4.

    CAS  Article  Google Scholar 

Download references

Funding

This work was supported by research grants from JSPS KAKENHI (19K17860, HU).

Author information

Affiliations

Authors

Contributions

HU and KK wrote the manuscript. All authors approved the final version.

Corresponding author

Correspondence to Hiroshi Ureshino.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ureshino, H., Kamachi, K. Vascular events may predict the prognosis of patients with chronic myeloid leukemia. Int J Hematol (2020). https://doi.org/10.1007/s12185-020-02889-8

Download citation